LAB
Standard Biotools Inc
NASDAQ: LAB · HEALTHCARE · MEDICAL DEVICES
$1.00
-1.72% today
Updated 2026-06-03
Market cap
$324.80M
P/E ratio
—
P/S ratio
3.77x
EPS (TTM)
$-0.13
Dividend yield
—
52W range
$1 – $2
Volume
3.7M
WallStSmart proprietary scores
45
out of 100
Grade: C
Sell
Investment rating
3.3
Growth
D7.0
Quality
B+4.0
Profitability
C5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-1.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →205 stocks currently score above 75
Price targets
Analyst target
$1.55
+55.05%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 90.70% — above average
+ Debt/equity 0.05x — low leverage
Risks
- Altman Z -1.01 — distress zone
- Negative free cash flow $-47.17M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $97.95M | $106.34M | $174.43M | $85.33M | $86.25M |
| Net income | $-190.10M | $-74.66M | $-138.88M | $-74.90M | $-45.22M |
| EPS | — | — | — | — | $-0.13 |
| Free cash flow | $-93.19M | $-46.12M | $-151.81M | $-82.65M | $-47.17M |
| Profit margin | -194.08% | -70.21% | -79.62% | -87.77% | 90.70% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-20 | MACKAY, SEAN | Sale | 25,729 | $1.00 |
| 2026-05-20 | KIM, HANJOON ALEX | Sale | 18,871 | $1.00 |
| 2026-05-20 | EGHOLM, MICHAEL | Sale | 97,626 | $1.00 |
Peer comparison
Smart narrative
Standard Biotools Inc trades at $1.00. Our Smart Value Score of 45/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -1.01, it sits in the distress. TTM revenue stands at $86.25M. with profit margins at 90.70%.
Frequently asked questions
What is Standard Biotools Inc's stock price?
Standard Biotools Inc (LAB) trades at $1.00, on a P/S of 3.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Standard Biotools Inc overvalued?
Standard Biotools Inc carries a Smart Value Score of 45/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Standard Biotools Inc (LAB)?
The 12-month analyst consensus target is $1.55, about 55.0% above the current $1.00. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Standard Biotools Inc's revenue?
Standard Biotools Inc's trailing twelve-month revenue is $86.25M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Standard Biotools Inc's Altman Z-Score is -1.01, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.77x
ROE-16.77%
Beta1.38
50D MA$0.97
200D MA$1.20
Shares out0.39B
Float0.21B
Short ratio—
Avg volume3.7M
Performance
1 week+0.00%
1 month+7.55%
3 months+15.78%
YTD-10.94%
1 year—
3 years—
5 years—